Hepatocardial relationships in non-alcoholic fatty liver disease: issues of epidemiology, diagnosis, prognosis

Abstract

World statistics indicate a steady increase in the prevalence of non-alcoholic fatty liver disease, which correlates with the pandemics of obesity and diabetes, which are quite common in Russia. The commonality of cardiometabolic risk factors, the high global prevalence of non-alcoholic fatty liver disease and atherosclerotic cardiovascular diseases generates the interest of researchers in studying hepatocardial relationships. Currently, non-alcoholic fatty liver disease is positioned as a hepatic manifestation of a multisystem disorder, heterogeneous in underlying causes, manifestations, course and outcomes. The purpose of this review was to analyze hepatocardial relationships based on publications. 76 sources on the epidemiology of non-alcoholic fatty liver disease, published from 2011–2023 in journals indexed in Pubmed and eLibrary, were analyzed. Age and gender aspects of the development of non-alcoholic fatty liver disease were considered. The pathogenetic mechanisms of hepatocardial relationships, which were closely related to systemic inflammation, insulin resistance, metabolic syndrome and its components, were highlighted. The criteria and methods for diagnosing non-alcoholic fatty liver disease and metabolic-associated liver disease were outlined. Recent studies demonstrated the presence of hepatocardial connections, characterized by an increased risk of developing atherosclerosis, cardiomyopathy and rhythm disturbances, changes in the structural and functional parameters and geometry of the heart, as well as diastolic dysfunction, which may precede and/or contribute to the development of chronic heart failure in patients with non-alcoholic fatty liver disease. The article presents data on non-alcoholic fatty liver disease as a new factor associated with the development of adverse cardiovascular events to a greater extent than the outcome of liver diseases themselves, which confirms the need for primary and secondary prevention of cardiovascular diseases in this cohort of patients.

Keywords

non-alcoholic fatty liver disease / cardiovascular diseases / diagnostics / epidemiology / forecast

References

[1] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368

[2] McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // Eur Heart J. 2021. Vol. 42, N. 36. P. 3599–3726. doi: 10.1093/eurheartj/ehab368

[3] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology. 2023;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004

[4] Younossi Z.M., Golabi P., Paik J.M., et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review // Hepatology. 2023. Vol. 77, N. 4. P. 1335–1347. doi: 10.1097/HEP.0000000000000004

[5] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84. doi: 10.1002/hep.28431

[6] Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. 2016. Vol. 64. P. 73–84. doi: 10.1002/hep.28431

[7] Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Wan ZH, Tang NSY, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD prevalence: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e28. doi: 10.1016/j.cgh.2021.12.002

[8] Le M.H., Yeo Y.H., Li X., et al. 2019 Global NAFLD Prevalence: A systematic review and meta-analysis // Clin Gastroenterol Hepatol. 2022. Vol. 20, N. 12. P. 2809–2817.e28. doi: 10.1016/j.cgh.2021.12.002

[9] Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, Toyoda H, Wong VW, Cheung R, Zhu Q, Nguyen MH. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389–398. doi: 10.1016/S2468-1253(19)30039-1

[10] Li J., Zou B., Yeo Y.H., et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis // Lancet Gastroenterol Hepatol. 2019. Vol. 4. P. 389–398. doi: 10.1016/S2468-1253(19)30039-1

[11] Drapkina O, Evsyutina Y, Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. Am J Clin Med Res. 2015;3(2):31–36. (In Russ.) doi: 10.12691/ajcmr-3-2-3

[12] Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of non-alcoholic fatty liver disease in the Russian Federation: The open, multicenter, prospective study, DIREG 1 // Am J Clin Med Res. 2015. Vol. 3, N. 2. P. 31–36. doi: 10.12691/ajcmr-3-2-3

[13] Ivashkin VT, Drapkina OM, Mayev IV, Trukhmanov AS, Blinov DV, Palgova LK, Tsukanov VV, Ushakova TI. Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(6):31–41. (In Russ.) EDN: VOXFQP

[14] Ивашкин В.Т., Драпкина О.М., Маев И.В., и др. Распространённость неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG 2 // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015. T. 6. C. 31–41. EDN: VOXFQP

[15] Ivashkin VT, Zharkova MS, Korochanskaya NV, Khlynov IB, Uspensky YuP. Phenotypes of non-alcoholic fatty liver disease in different regions of the Russian Federation, diagnostic and therapeutic approach in clinical practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(2):7–18. (In Russ.) doi: 10.22416/1382-4376-2023-33-2-7-18

[16] Ивашкин В.Т., Жаркова М.С., Корочанская Н.В., и др. Фенотипы неалкогольной жировой болезни печени в различных регионах Российской Федерации, диагностические и лечебные подходы в клинической практике // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2023. T. 33, № 2. C. 7–18. doi: 10.22416/1382-4376-2023-33-2-7-18

[17] Maev IV, Andreev DN, Kucheryavyy YA. Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis. Consilium Medicum. 2023;25(5):313–319. (In Russ.) doi: 10.26442/20751753.2023.5.202155

[18] Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Распространённость неалкогольной жировой болезни печени в России: мета-анализ // Consilium Medicum. 2023. T. 25, № 5. C. 313–319. doi: 10.26442/20751753.2023.5.202155

[19] Drapkina OM, Ivashkin VT. Epidemiological features of non-alcoholic fatty liver disease in Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(4):32–38. (In Russ.) EDN: TEZCYF

[20] Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014. Т. 24, № 4. C. 32–38. EDN: TEZCYF

[21] Platonova OE, Roitberg GE, Sharkhun OO. Features of the ultrasound picture of the hepatobiliary system and pancreas in patients with non-alcoholic fatty liver disease. Novainfo.ru. 2017;2(59):400–405. (In Russ.) EDN: XVQFMH

[22] Платонова О.Е., Ройтберг Г.Е., Шархун О.О. Особенности ультразвуковой картины гепатобилиарной системы и поджелудочной железы у пациентов с неалкогольной жировой болезнью печени // Novainfo.ru. 2017. Т. 2, № 59. C. 400–405. EDN: XVQFMH

[23] Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, Shiratori K. The characteristics and natural history of Japan patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33(2):72–76. doi: 10.1016/j.hepres.2005.09.007

[24] Hashimoto E., Yatsuji S., Kaneda H., et al. The characteristics and natural history of Japan patients with nonalcoholic fatty liver disease // Hepatol Res. 2005. Vol. 33, N. 2. P. 72–76. doi: 10.1016/j.hepres.2005.09.007

[25] Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex differences in nonalcoholic fatty liver disease: State of the art and identification of research gaps. Hepatology. 2019;70(4):1457–1469. doi: 10.1002/hep.30626

[26] Lonardo A., Nascimbeni F., Ballestri S., et al. Sex differences in nonalcoholic fatty liver disease: State of the art and identification of research gaps // Hepatology. 2019. Vol. 70, N. 4. P. 1457–1469. doi: 10.1002/hep.30626

[27] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34(6):1291–1326. doi: 10.1007/s12325-017-0556-1

[28] Ballestri S., Nascimbeni F., Baldelli E., et al. NAFLD as a sexual dimorphic disease: Role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk // Adv Ther. 2017. Vol. 34, N. 6. P. 1291–1326. doi: 10.1007/s12325-017-0556-1

[29] Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi: 10.1016/j.jhep.2020.03.039

[30] Eslam M., Newsome P.N., Sarin S.K., et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement // J Hepatol. 2020. Vol. 73, N. 1. P. 202–209. doi: 10.1016/j.jhep.2020.03.039

[31] Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172–2181.e6. doi: 10.1016/j.cgh.2021.05.029

[32] Nguyen V.H., Le M.H., Cheung R.C., Nguyen M.H. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD // Clin Gastroenterol Hepatol. 2021. Vol. 19, N. 10. P. 2172–2181.e6. doi: 10.1016/j.cgh.2021.05.029

[33] Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J (Engl). 2021;134(13):1593–1601. doi: 10.1097/CM9.0000000000001513

[34] Zhang H.J., Wang Y.Y., Chen C., et al. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016 // Chin Med J (Engl). 2021. Vol. 134, N. 13. P. 1593–1601. doi: 10.1097/CM9.0000000000001513

[35] Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67:1265–1273. doi: 10.1016/j.jhep.2017.07.027

[36] Hagström H., Nasr P., Ekstedt M., et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD // J Hepatol. 2017. Vol. 67. P. 1265–1273. doi: 10.1016/j.jhep.2017.07.027

[37] Inciardi RM, Mantovani A, Targher G. Non-alcoholic fatty liver disease as an emerging risk factor for heart failure. Curr Heart Fail Rep. 2023;20(4):308–319. doi: 10.1007/s11897-023-00613-1

[38] Inciardi R.M., Mantovani A., Targher G. Non-alcoholic fatty liver disease as an emerging risk factor for heart failure // Curr Heart Fail Rep. 2023. Vol. 20, N. 4. P. 308–319. doi: 10.1007/s11897-023-00613-1

[39] Mantovani A, Scorletti E, Mosca A, Alis A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S:154170. doi: 10.1016/j.metabol.2020.154170

[40] Mantovani A., Scorletti E., Mosca A., et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease // Metabolism. 2020. Vol. 111. P. 154170. doi: 10.1016/j.metabol.2020.154170

[41] Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-lancet liver commission: Protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61–116. doi: 10.1016/S0140-6736(21)01701-3

[42] Karlsen T.H., Sheron N., Zelber-Sagi S , et al. The EASL-lancet liver commission: Protecting the next generation of Europeans against liver disease complications and premature mortality // Lancet. 2022. Vol. 399, N. 10319. P. 61–116. doi: 10.1016/S0140-6736(21)01701-3

[43] Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO); Members of the guidelines panel; Coordinator; AISF Members; SID Members; SIO Members; Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis. 2022;32(1):1–16. doi: 10.1016/j.numecd.2021.04.028

[44] Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO); Members of the guidelines panel; Coordinator; AISF Members; SID Members; SIO Members; Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) // Nutr Metab Cardiovasc Dis. 2022. Vol. 32, N. 1. P. 1–16. doi: 10.1016/j.numecd.2021.04.028

[45] Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323

[46] Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease // Hepatology. 2023. Vol. 77, N. 5. P. 1797–1835. doi: 10.1097/HEP.0000000000000323

[47] Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT, Kuznetsova EI. Nealkogol'naia zhirovaia bolezn' pecheni s pozitsii sovremennoi meditsiny. (Non-alcoholic fatty liver disease from the perspective of modern medicine.) Moscow: Prima Print, 2020. 68 p. (In Russ.) Available from: https://www.mucofalk.ru/wp-content/uploads/2023/02/46.pdf?ysclid=m4lulyjoks883853525 Accessed: Dec 14, 2023.

[48] Маев И.В., Андреев Д.Н., Кучерявый Ю.А., и др. Неалкогольная жировая болезнь печени с позиций современной медицины. Москва: Прима Принт, 2020. C. 68. Режим доступа: https://www.mucofalk.ru/wp-content/uploads/2023/02/46.pdf?ysclid=m4lulyjoks883853525 Дата обращения: 14.12.2023.

[49] Ivashkin VT, Maevskaya MV, Zharkova MS, Kotovskaya YV, Tkacheva ON, Troshina EA, Shestakova MV, Maev IV, Breder VV, Gheivandova NI, Doshchitsin VL, Dudinskaya EN, Ershova EV, Kodzoeva KB, Komshilova KA, Korochanskaya NV, Mayorov AY, Mishina EE, Nadinskaya MYu, Nikitin IG, Pogosova NV, Tarzimanova AI, Shamkhalova MS. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for preventive cardiology on diagnosis and treatment of non-alcoholic liver disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104–140. (In Russ.) doi: 10.22416/1382-4376-2022-32-4-104-140

[50] Ивашкин В.Т., Маевская М.В., Жаркова М.С., и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022. T. 32, № 4. C. 104–140. doi: 10.22416/1382-4376-2022-32-4-104-140

[51] Maev IV, Andreev DN. Non-alcoholic fatty liver disease: mechanisms of development, clinical forms and drug correction. Consilium Medicum. Gastroenterologiya. 2012;(2):36–39. (In Russ.) EDN: SXTRNT

[52] Маев И.В., Андреев Д.Н. Неалкогольная жировая болезнь печени: механизмы развития, клинические формы и медикаментозная коррекция // Consilium Medicum. Гастроэнтерология. 2012. № 2. C. 36–39. EDN: SXTRNT

[53] Vovk EI. Nonalcoholic fatty liver disease as pro-atherogenic disease: diagnosis and treatment in general practice. RMJ. Medical Review. 2017;(2):68–79. (In Russ.) EDN: YLAYYM

[54] Вовк Е.И. Неалкогольная жировая болезнь печени как проатерогенное заболевание: диагностика и лечение в общей практике // РМЖ. Медицинское обозрение. 2017. № 2. C. 68–79. EDN: YLAYYM

[55] Sadulaeva IA, Yushchuk EN, Khalikova LF, Krikunova OV, Trofimenko OS, Medvedeva EG. Subclinical markers of liver damage in patients with arterial hypertension and obesity. Therapeutic archive. 2022;94(12):1367–1373. (In Russ.) doi: 10.26442/00403660.2022.12.201993

[56] Садулаева И.А., Ющук Е.Н., Халикова Л.Ф., и др. Субклинические маркёры поражения печени у больных артериальной гипертензией и ожирением // Терапевтический архив. 2022. T. 94, № 12. C. 1367–1373. doi: 10.26442/00403660.2022.12.201993

[57] Giallourakis CC. Liver complications in patients with congestive heart failure. Gastroenterol Hepatol (NY)/ 2013;9:244–246. PMID: 24711770

[58] Giallourakis C.C. Liver complications in patients with congestive heart failure // Gastroenterol Hepatol (NY). 2013. Vol. 9. P. 244–246. PMID: 24711770

[59] Wong F, Greenbloom S, Blendis L. The liver in heart failure. In: Friedman L, Keeffe E. Handbook of liver disease. 2nd ed. Philadelphia: Churchill Livingstone; 2004. p. 257–268. doi: 10.1016/B978-0-443-06633-7.50025-9

[60] Wong F., Greenbloom S., Blendis L. The liver in heart failure. In: Friedman L., Keeffe E. Handbook of liver disease. 2nd ed. Philadelphia: Churchill Livingstone, 2004. P. 257–268. doi: 10.1016/B978-0-443-06633-7.50025-9

[61] European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. European guidelines regarding the diagnosis and management of NAFLD and its advanced forms. J Hepatol. 2016;64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004

[62] European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. European guidelines regarding the diagnosis and management of NAFLD and its advanced forms // J Hepatol. 2016. Vol. 64, N. 6. P. 1388–1402. doi: 10.1016/j.jhep.2015.11.004

[63] Byrne CD, Patel J, Scorletti E, Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. BMJ. 2018;362:k2734. doi: 10.1136/bmj.k2734

[64] Byrne C.D., Patel J., Scorletti E., Targher G. Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults // BMJ. 2018. Vol. 362. P. k2734. doi: 10.1136/bmj.k2734

[65] Aldasheva ZhA. Non-alcoholic fatty liver disease: the role of ultrasound in its diagnosis. Vestnik KRSU. 2013;13(11):28–31. (In Russ.) EDN: SNGUGV

[66] Алдашева Ж.А. Неалкогольная жировая болезнь печени: роль ультразвукового метода исследования в её диагностике // Вестник КРСУ. 2013. Т. 13, № 11. С. 28–31. EDN: SNGUGV

[67] Zhirkov II, Gordienko AV, Pavlovich IM, Golofeevsky VYu., Makoveeva OV. Noninvasive methods of diagnosis of steatosis in non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;177(5):61–66. (In Russ.) doi: 10.31146/1682-8658-ecg-177-5-61-66

[68] Жирков И.И., Гордиенко А.В., Павлович И.М., и др. Неинвазивные методы диагностики стеатоза при неалкогольной жировой болезни печени // Экспериментальная и клиническая гастроэнтерология. 2020. Т. 177, № 5. С. 61–66. doi: 10.31146/1682-8658-ecg-177-5-61-66

[69] Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508. doi: 10.1016/j.dld.2009.08.002

[70] Lee J.H., Kim D., Kim H.J., et al. Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease // Dig Liver Dis. 2010. Vol. 42, N. 7. P. 503–508. doi: 10.1016/j.dld.2009.08.002

[71] Statsenko ME, Turkina SV, Kosivtsova MA, Shilina NN. Non-invasive diagnosis of non-alcoholic fatty liver disease: simple “tools” are already in the hands of a practicing doctor. Bulletin of VolSMU. 2019;(2):134–139. (In Russ.) doi: 10.19163/1994-9480-2019-2(70)-134-139

[72] Стаценко М.Е., Туркина С.В., Косивцова М.А., Шилина Н.Н. Неинвазивная диагностика неалкогольной жировой болезни печени: простые «инструменты» уже в руках практического врача // Вестник Волгоградского государственного медицинского университета. 2019. № 2. С. 134–139. doi: 10.19163/1994-9480-2019-2(70)-134-139

[73] Roitberg GE, Sharhun OO. Assessment of risk factors for nonalcoholic fatty liver disease. Lechashchii vrach. 2017;(1):58–62. (In Russ.) EDN: YHOFJF

[74] Ройтберг Г.Е., Шархун О.О. Оценка факторов риска неалкогольной жировой болезни печени // Лечащий врач. 2017. № 1. С. 58–62. EDN: YHOFJF

[75] Lazebnik LB, Radchenko VG, Golovanova ЕV, Zvenigorodskaya LA, Konev YuV, Seliverstov PV, Sitkin SI, Tkachenko EI, Avalueva EB, Ailamazyan EK, Vlasov NN, Grinevich VB, Korniyenko EA, Novikova VP, Khoroshinina LP, Zhestkova NV, Oreshko LS, Dudanova OP, Dobritsa VP, Turieva LV, Tirikova OV, Kozlova NM, Yeliseev SM, Gumerov RR, Ventsak EV, Aleshina EI, Gurova MM, Goryacheva LG. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment (guidelines for the specialists on internal medicine, 2nd version). Terapiya. 2017;(3):5–23. (In Russ.) EDN: YQZFEZ

[76] Лазебник Л.Б., Радченко В.Г., Голованова Е.В., и др. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение (рекомендации для терапевтов, 2-я версия) // Терапия. 2017. № 3. С. 5–23. EDN: YQZFEZ

[77] Drapkina OM. RAAS and fibrosis. Hepatocardial connections. Russkiy meditsinkiy zhurnal. 2011;19(18):1136–1139. (In Russ.) EDN: QZIYLF

[78] Драпкина О.М. РААС и фиброз. Гепатокардиальные связи // РМЖ. 2011. Т. 19, № 18. С. 1136–1139. EDN: QZIYLF

[79] Eslam M, Sanyal AJ, George J; International Consensus P. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014. doi: 10.1053/j.gastro.2019.11.312

[80] Eslam M., Sanyal A.J., George J.; International Consensus P. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease // Gastroenterology. 2020. Vol. 158, N. 7. P. 1999–2014. doi: 10.1053/j.gastro.2019.11.312

[81] Maev IV, Andreev DN, Kucheriavyi YuA, Umyarova RM. Metabolicheski assotsiirovannaya zhirovaya bolezn' pecheni. (Metabolic-associated fatty liver disease.) Moscow: Prima Print; 2021. 72 p. (In Russ.)

[82] Маев И.В., Андреев Д.Н., Кучерявый Ю.А., Умярова Р.М. Метаболически ассоциированная жировая болезнь печени. Москва: Прима Принт, 2021. 72 с.

[83] Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021;32(7):500–514. doi: 10.1016/j.tem.2021.04.008

[84] Lim S., Kim J.W., Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease // Trends Endocrinol Metab. 2021. Vol. 32, N. 7. P. 500–514. doi: 10.1016/j.tem.2021.04.008

[85] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012

[86] Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) // Metabolism. 2016. Vol. 65, N. 8. P. 1038–1048. doi: 10.1016/j.metabol.2015.12.012

[87] Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: An overview. Hepatol Commun. 2020;4(4):478–792. doi: 10.1002/hep4.147922

[88] Parthasarathy G., Revelo X., Malhi H. Pathogenesis of nonalcoholic steatohepatitis: An overview // Hepatol Commun. 2020. Vol. 4, N. 4. P. 478–492. doi: 10.1002/hep4.147922

[89] Martín-Mateos R, Albillos A. The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease. Front Immunol. 2021;12:660179. doi: 10.3389/fimmu.2021.66017923

[90] Martín-Mateos R., Albillos A. The role of the gut-liver axis in metabolic dysfunction-associated fatty liver disease // Front Immunol. 2021. Vol. 12. P. 660179. doi: 10.3389/fimmu.2021.66017923

[91] Dicheva DT, Andreev DN. Pathogenetic and clinical significance of the gut-liver microbiota axis. Meditsinskiy sovet. 2022;(7):69–75. (In Russ.) doi: 10.21518/2079-701X-2022-16-7-69-75

[92] Дичева Д.Т., Андреев Д.Н. Патогенетическое и клиническое значение оси «микробиота — кишечник — печень» // Медицинский совет. 2022. № 7. С. 69–75. doi: 10.21518/2079-701X-2022-16-7-69-75

[93] Pashentseva AV, Verbovoy AF, Sharonova LA. Insulin resistance in therapeutic clinic. Obesity and metabolism. 2017;14(2):9–17. (In Russ.) doi: 10.14341/omet201729-17

[94] Пашенцева А.В., Вербовой А.Ф., Шаронова Л.А. Инсулинорезистентность в терапевтической клинике // Ожирение и метаболизм. 2017. Т. 14, № 2. С. 9–17. doi: 10.14341/omet201729-17

[95] Ermolova TV, Ermolov SY, Belyayeva EL. Non-alcoholic fatty liver disease: a modern approach to the problem. Effektivnaya Farmakoterapiya. 2016;(5):26–35. (In Russ.) EDN: VQHCDF

[96] Ермолова Т.В., Ермолов С.Ю., Беляева Е.Л. Неалкогольная жировая болезнь печени: современный взгляд на проблему // Эффективная фармакотерапия. 2016. № 5. С. 26–35. EDN: VQHCDF

[97] Balukova EV, Baryshnikova NV, Belousova LN. Non-alcoholic fatty liver disease: current state problem. Pharmateka. 2016;(2):63–68. (In Russ.) EDN: VMICPV

[98] Балукова Е.В., Барышникова Н.В., Белоусова Л.Н. Неалкогольная жировая болезнь печени: современное состояние проблемы // Фарматека. 2016. T. 2. С. 63–68. EDN: VMICPV

[99] Gaus OV, Akhmedov VA. Pathogenetic features of the hepatobiliary system damage in patients with metabolic syndrome. Kazan Medical Journal. 2014;95(1):70–74. (In Russ.) doi: 10.17816/KMJ1459

[100] Гаус О.В., Ахмедов В.А. Патогенетические особенности поражения органов гепатобилиарной системы у больных с метаболическим синдромом // Казанский медицинский журнал. 2014. Т. 95, № 1. С. 70–74. doi: 10.17816/KMJ1459

[101] Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(8):948–963. doi: 10.1016/j.jacc.2018.11.050

[102] Stahl E.P., Dhindsa D.S., Lee S.K., et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review // J Am Coll Cardiol. 2019. Vol. 73, N. 8. P. 948–963. doi: 10.1016/j.jacc.2018.11.050

[103] Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2018;15(7):425–439. doi: 10.1038/s41575-018-0010-0

[104] Anstee Q.M., Mantovani A., Tilg H., Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease // Nat Rev Gastroenterol Hepatol. 2018. Vol. 15, N. 7. P. 425–439. doi: 10.1038/s41575-018-0010-0

[105] Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79(2):180–191. doi: 10.1016/j.jacc.2021.11.007

[106] Mantovani A., Byrne C.D., Benfari G., et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week // J Am Coll Cardiol. 2022. Vol. 79, N. 2. P. 180–191. doi: 10.1016/j.jacc.2021.11.007

[107] Vasconcelos L, Almeida E, Bachur L. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. Arq Bras Cardiol. 2007;88(5):590–595. doi: 10.1590/s0066-782x2007000500015

[108] Vasconcelos L., Almeida E., Bachur L. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure // Arq Bras Cardiol. 2007. Vol. 88, N. 5. P. 590–595. doi: 10.1590/s0066-782x2007000500015

[109] Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis. 2002;6(4):947–967. doi: 10.1016/s1089-3261(02)00056-9

[110] Giallourakis C.C., Rosenberg P.M., Friedman L.S. The liver in heart failure // Clin Liver Dis. 2002. Vol. 6, N. 4. P. 947–967. doi: 10.1016/s1089-3261(02)00056-9

[111] Mantovani A, Csermely A, Petracca G, Beatrice G, Corey KE, Simon TG, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(11):903–913. doi: 10.1016/S2468-1253(21)00308-3

[112] Mantovani A., Csermely A., Petracca G., et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis // Lancet Gastroenterol Hepatol. 2021. Vol. 6, N. 11. P. 903–913. doi: 10.1016/S2468-1253(21)00308-3

[113] Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP. American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):168–185. doi: 10.1161/ATV.0000000000000153

[114] Duell P.B., Welty F.K., Miller M., et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Hypertension; Council on the Kidney in Cardiovascular Disease; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association // Arterioscler Thromb Vasc Biol. 2022. Vol. 42, N. 6. P. 168–185. doi: 10.1161/ATV.0000000000000153

[115] Roytberg GE, Sharhun OO. Clinical outcomes in patients with non-alcoholic fatty liver disease and insulin resistance after 5 years of follow-up. Spravochnik vracha obshchey praktiki. 2018;(5):57–63. (In Russ.) EDN: XZBUGD

[116] Ройтберг Г.Е., Шархун О.О. Клинические исходы у пациентов с неалкогольной жировой болезнью печени и инсулинорезистентностью через 5 лет наблюдения // Справочник врача общей практики. 2018. № 5. С. 57–63. EDN: XZBUGD

[117] Kapuria D, Takyar VK, Etzion O, Surana P, O'Keefe JH, Koh C. Association of hepatic steatosis with subclinical atherosclerosis: Systematic review and meta-analysis. Hepatol Commun. 2018;2(8):873–883. doi: 10.1002/hep4.1199

[118] Kapuria D., Takyar V.K., Etzion O., et al. Association of hepatic steatosis with subclinical atherosclerosis: Systematic review and meta-analysis // Hepatol Commun. 2018. Vol. 2, N. 8. P. 873–883. doi: 10.1002/hep4.1199

[119] Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, Zheng MH. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun. 2018;2(4):376–392. doi: 10.1002/hep4.1155

[120] Zhou Y.Y., Zhou X.D., Wu S.J., et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis // Hepatol Commun. 2018. Vol. 2, N. 4. P. 376–392. doi: 10.1002/hep4.1155

[121] Minhas AMK, Jain V, Maqsood MH, Pandey A, Khan SS, Fudim M, Fonarow GC, Butler J, Khan MS. Non-alcoholic fatty liver disease, heart failure, and long-term mortality: Insights from the national health and nutrition examination survey. Curr Probl Cardiol. 2022;47(12):101333. doi: 10.1016/j.cpcardiol.2022.101333

[122] Minhas A.M.K., Jain V., Maqsood M.H., et al. Non-alcoholic fatty liver disease, heart failure, and long-term mortality: Insights from the national health and nutrition examination survey // Curr Probl Cardiol. 2022. Vol. 47, N. 12. P. 101333. doi: 10.1016/j.cpcardiol.2022.101333

[123] Wu S, Wu F, Ding Y, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386. doi: 10.1038/srep33386

[124] Wu S., Wu F., Ding Y., et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis // Sci Rep. 2016. Vol. 6. P. 33386. doi: 10.1038/srep33386

[125] Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, Kobayashi T, Nogami A, Higurashi T, Kato S, Hosono K, Saito S, Nakajima A. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–1032. doi: 10.1007/s00535-021-01828-6

[126] Yoneda M., Yamamoto T., Honda Y., et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: A retrospective nationwide claims database study in Japan // J Gastroenterol. 2021. Vol. 56, N. 11. P. 1022–1032. doi: 10.1007/s00535-021-01828-6

[127] Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi: 10.1038/nrgastro.2016.147

[128] Tilg H., Moschen A.R., Roden M. NAFLD and diabetes mellitus // Nat Rev Gastroenterol Hepatol. 2017. Vol. 14, N. 1. P. 32–42. doi: 10.1038/nrgastro.2016.147

[129] Park HE, Lee H, Choi SY, Kwak MS, Yang JI, Yim JY, Chung GE. Clinical significance of hepatic steatosis according to coronary plaque morphology: Assessment using controlled attenuation parameter. J Gastroenterol. 2019;54:271–280. doi: 10.1007/s00535-018-1516-5

[130] Park H.E., Lee H., Choi S.Y., et al. Clinical significance of hepatic steatosis according to coronary plaque morphology: Assessment using controlled attenuation parameter // J Gastroenterol. 2019. Vol. 54. P. 271–280. doi: 10.1007/s00535-018-1516-5

[131] Lee YH, Kim KJ, Yoo ME, Kim G, Yoon HJ, Jo K, Youn JC, Yun M, Park JY, Shim CY, Lee BW, Kang SM, Ha JW, Cha BS, Kang ES. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol. 2018;68(4):764–772. doi: 10.1016/j.jhep.2017.11.023

[132] Lee Y.H., Kim K.J., Yoo M.E., et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients // J Hepatol. 2018. Vol. 68, N. 4. P. 764–772. doi: 10.1016/j.jhep.2017.11.023

[133] Drapkina OM, Zyatenkova EV. Evaluation of cardiovascular remodeling and epicardial fat thickness in patients with chronic heart failure and metabolic syndrome. Therapeutic Archive. 2016;88(2):64–70. (In Russ.) doi: 10.17116/terarkh201688264-70

[134] Драпкина О.М., Зятенкова Е.В. Оценка ремоделирования сердечно-сосудистой системы и толщины эпикардиального жира у пациентов с хронической сердечной недостаточностью и метаболическим синдромом // Терапевтический архив. 2016. Т. 88, № 2. С. 64–70. doi: 10.17116/terarkh201688264-70

[135] Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, Bertolini L, Valbusa F, Barbieri E, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS One. 2015;10(8):e0135329. doi: 10.1371/journal.pone.0135329

[136] Mantovani A., Pernigo M., Bergamini C., et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes // PLoS One. 2015. Vol. 10, N. 8. P. e0135329. doi: 10.1371/journal.pone.0135329

[137] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. doi: 10.1016/j.jhep.2016.05.013

[138] Targher G., Byrne C.D., Lonardo A., et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis // J Hepatol. 2016. Vol. 65, N. 3. P. 589–600. doi: 10.1016/j.jhep.2016.05.013

[139] Fudim M, Zhong L, Patel KV, Khera R, Abdelmalek MF, Diehl AM, McGarrah RW, Molinger J, Moylan CA, Rao VN, Wegermann K, Neeland IJ, Halm EA, Das SR, Pandey A. Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries. J Am Heart Assoc. 2021;10(22):e021654. doi: 10.1161/JAHA.121.021654

[140] Fudim M., Zhong L., Patel K.V., et al. Nonalcoholic fatty liver disease and risk of heart failure among medicare beneficiaries // J Am Heart Assoc. 2021. Vol. 10, N. 22. P. e021654. doi: 10.1161/JAHA.121.021654

[141] Li W, Wen W, Xie D, Qiu M, Cai X, Zheng S, Huang Y. Association between non-alcoholic fatty liver disease and risk of incident heart failure: A meta-analysis of observational studies. Ther Adv Chronic Dis. 2022;13:20406223221119626. doi: 10.1177/20406223221119626

[142] Li W., Wen W., Xie D., et al. Association between non-alcoholic fatty liver disease and risk of incident heart failure: A meta-analysis of observational studies // Ther Adv Chronic Dis. 2022. Vol. 13. P. 20406223221119626. doi: 10.1177/20406223221119626

[143] Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of new-onset heart failure: An updated meta-analysis of about 11 million individuals. Gut. 2022;112(10):327672. doi: 10.1136/gutjnl-2022-327672

[144] Mantovani A., Petracca G., Csermely A., et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: An updated meta-analysis of about 11 million individuals // Gut. 2022. Vol. 112, N. 10. P. 327672. doi: 10.1136/gutjnl-2022-327672

[145] Wijarnpreecha K, Lou S, Panjawatanan P, Cheungpasitporn W, Pungpapong S, Lukens FJ, Ungprasert P. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis. 2018;50(11):1166-1175. doi: 10.1016/j.dld.2018.09.004.

[146] Wijarnpreecha K., Lou S., Panjawatanan P., et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis // Dig Liver Dis. 2018. Vol. 50, N. 11. P. 1166–1175. doi: 10.1016/j.dld.2018.09.004

[147] Simon TG, Roelstraete B, Hagstrom H, Sundstrom J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: Results from a nationwide histology cohort. Gut. 2022;71(9):1867–1875. doi: 10.1136/gutjnl-2021-325724

[148] Simon T.G., Roelstraete B., Hagstrom H., et al. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort // Gut. 2022. Vol. 71, N. 9. P. 1867–1875. doi: 10.1136/gutjnl-2021-325724

[149] Andreev DN, Kucheryavyy YuA. Obesity as a risk factor for diseases of the digestive system. Therapeutic Archive. 2021;93(8):954–962. (In Russ.) doi: 10.26442/00403660.2021.08.200983

[150] Андреев Д.Н., Кучерявый Ю.А. Ожирение как фактор риска заболеваний пищеварительной системы // Терапевтический архив. 2021. T. 93, № 8. C. 954–962. doi: 10.26442/00403660.2021.08.200983

[151] Maev IV, Andreev DN, Kucheryavyy YuA. Metabolically associated fatty liver disease — a disease of the 21st century. Consilium Medicum. 2022;24(5):325–332 (In Russ.) doi: 10.26442/20751753.2022.5.201532

[152] Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Метаболически ассоциированная жировая болезнь печени — заболевание XXI века // Consilium Medicum. 2022. T. 24, № 5. С. 325–332. doi: 10.26442/20751753.2022.5.201532

RIGHTS & PERMISSIONS

Eco-Vector